{
    "data": [
        {
            "id": "4657896",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-14T11:38:30-05:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442103942/image_1442103942.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "509249",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4657896-vertexs-pain-game-vx-548-takes-aim-at-neuropathic-battles"
            }
        },
        {
            "id": "4656952",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-08T20:06:38-05:00",
                "isLockedPro": false,
                "commentCount": 75,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1186545957/image_1186545957.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "507973",
                            "type": "sentiment"
                        },
                        {
                            "id": "507972",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4656952-vertex-and-crispr-therapeutics-historic-exa-cel-approval-why-market-is-nonplussed"
            }
        },
        {
            "id": "4652562",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-16T23:16:56-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182484339/image_182484339.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals Looks Expensive, Though It Isn't",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105995",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "502474",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4652562-vertex-pharmaceuticals-q3-earnings-looks-expensive-it-isnt"
            }
        },
        {
            "id": "4648726",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-07T17:27:22-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/668600179/image_668600179.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "No Dividend, No Problem: Vertex Pharmaceuticals Continues To Compound Wealth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "500110",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4648726-no-dividend-no-problem-vertex-pharmaceuticals-continues-to-compound-wealth"
            }
        },
        {
            "id": "4639681",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-09T14:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1330738572/image_1330738572.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals Deserves Its Monopoly Premium Indeed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "491592",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4639681-vertex-pharmaceuticals-deserves-monopoly-premium-indeed"
            }
        },
        {
            "id": "4636355",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-20T16:35:50-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310024666/image_1310024666.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Total Return Superstar: Vertex Pharmaceuticals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "487307",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4636355-a-total-return-superstar-vertex-pharma"
            }
        },
        {
            "id": "4632273",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-31T09:43:19-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1458140515/image_1458140515.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: Critical Period For The Pipeline Is Approaching",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "482280",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4632273-vertex-pharmaceuticals-critical-period-for-the-pipeline-is-approaching"
            }
        },
        {
            "id": "4627909",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-13T04:55:35-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418835107/image_1418835107.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals Still Looks Attractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "477580",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4627909-vertex-pharmaceuticals-stock-attractive"
            }
        },
        {
            "id": "4626889",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-10T14:50:27-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1598361009/image_1598361009.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Continued Advances In Cystic Fibrosis Market With Expansion Plans",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "477278",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4626889-vertex-continued-advances-in-cystic-fibrosis-market-with-expansion-plans"
            }
        },
        {
            "id": "4626562",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-10T10:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/643782354/image_643782354.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: Strategically Positioning For Future Success",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "477050",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4626562-vertex-pharmaceuticals-strategically-positioning-for-future-success"
            }
        },
        {
            "id": "4621320",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-28T17:01:08-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171582228/image_171582228.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex And CRISPR Therapeutics - Partners On Exa-cel - But Unequally Valued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "474142",
                            "type": "sentiment"
                        },
                        {
                            "id": "474143",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4621320-vertex-and-crispr-therapeutics-partners-on-exa-cel-but-unequally-valued"
            }
        },
        {
            "id": "4615177",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-04T23:10:26-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1082582778/image_1082582778.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Promising Prospects Amid Stretched Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "467858",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615177-vertex-promising-prospects-amid-stretched-valuation"
            }
        },
        {
            "id": "4614964",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-03T11:55:43-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366552805/image_1366552805.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Resilient Growth And Promising Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106413",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "467887",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4614964-vertex-resilient-growth-and-promising-pipeline"
            }
        },
        {
            "id": "4607130",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-24T16:23:42-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1492224286/image_1492224286.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: CF Focus, Potential To Alter Acute Pain Treatment Market Landscape",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "458607",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4607130-vertex-cf-focus-potential-to-alter-acute-pain-treatment-market-landscape"
            }
        },
        {
            "id": "4605380",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-17T09:59:43-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/625758234/image_625758234.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals Rally Likely Not Over",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "456633",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4605380-vertex-pharmaceuticals-rally-likely-not-over"
            }
        },
        {
            "id": "4594102",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-14T10:45:01-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/667138644/image_667138644.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Crispr And Vertex: ICER Sheds Light On The Future Of Sickle Cell Treatment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59621",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "449872",
                            "type": "sentiment"
                        },
                        {
                            "id": "449873",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594102-crispr-vertex-icer-sheds-light-future-sickle-cell-treatment"
            }
        },
        {
            "id": "4592863",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-07T11:15:45-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/465531391/image_465531391.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: A Promising Portfolio After A Year Of Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106364",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "448448",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4592863-vertex-pharmaceuticals-a-promising-portfolio-after-a-year-of-growth"
            }
        },
        {
            "id": "4588713",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-20T09:47:41-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1317189603/image_1317189603.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals For Strong CF Franchise Growth Plus Exciting Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "444976",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4588713-vertex-strong-cf-franchise-growth-plus-exciting-pipeline"
            }
        },
        {
            "id": "4587949",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-16T12:44:14-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346213103/image_1346213103.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: On The Verge Of Becoming A Very Serious Proposition For Buyers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "444406",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4587949-vertex-verge-becoming-serious-proposition-buyers"
            }
        },
        {
            "id": "4576955",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-09T15:56:13-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/495358386/image_495358386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: As Strong As Ever In Cystic Fibrosis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "436776",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4576955-vertexpharmaceuticals-as-strong-as-ever-in-cystic-fibrosis"
            }
        },
        {
            "id": "4576551",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-08T18:52:10-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368429013/image_1368429013.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: Pioneering Scientific Advances To Tackle Serious Diseases",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59621",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "436570",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4576551-vertex-pharmaceuticals-scientific-advances-to-tackle-diseases"
            }
        },
        {
            "id": "4568881",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-09T23:13:19-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1419086950/image_1419086950.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Royalty Pharma: An Attractive Business Model But An Uncertain Outcome For Vertex's CF Royalties",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105578",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "430247",
                            "type": "sentiment"
                        },
                        {
                            "id": "430248",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4568881-royalty-pharma-attractive-business-model-uncertain-outcome-vertex-cf-royalties"
            }
        }
    ]
}